September 4, 2018

Thanks to a generous donation on behalf of the Harris County Houston Sports Authority, Texas Children’s was able to host a Peanut Allergy Friendly Day at the July 14 Houston Astros game against the Detroit Tigers. Eight families with children who are allergic to peanuts got to watch the game from an area filled with peanut-free foods.

Many children with allergies are not able to attend sporting events such as baseball games due to fear and anxiety of being exposed to foods such as peanuts. At an event like the Peanut Allergy Friendly Day, children with allergies can sit back, relax and really feel the energy and excitement we all experience when we attend an Astros game.

To learn more about allergies in children, sign up for Texas Children’s 5th annual Food Allergy Symposium. The event is from 8 a.m. to noon on Saturday, September 29, at the United Way Community Resource Center at 55 Waugh Drive, and will focus on educating the community about emerging therapies and new research initiatives. Experts will discuss the new Stock Epinephrine Bill, as well as practical coping strategies for children with established food allergies. We will have youth sessions for children and teens, a photo booth, live cooking demos from our clinical dietician, and interactive breakout sessions for caregivers. Register for this event here: www.texaschildrens.org/allergysymposium.

December 13, 2017

Dr. Carla Davis has been appointed the new head of the Section of Immunology, Allergy and Rheumatology and Chief of the Allergy/Immunology Service in the Department of Pediatrics at Baylor College of Medicine and Texas Children’s Hospital.

Dr. Jordan Orange, who currently holds this position, will be leaving Texas Children’s to become the new Chair of Columbia University’s Department of Pediatrics. Until his departure in the Spring 2018, Orange will work closely with Davis to ensure a smooth transition of leadership.

Davis earned an M.D. degree from Duke University Medical School in 1997. She completed pediatric residency training at Baylor and Texas Children’s, followed by postdoctoral fellowships in Allergy and Immunology (2001-2003) and HIV/AIDS Clinical Research (2000-2001 and 2003-2004). She joined the Baylor faculty as an assistant professor in 2005 and was promoted to associate professor in 2015. Davis is certified by both the American Board of Pediatrics and the American Board of Allergy and Immunology. She is an internationally recognized authority and investigator in the field of food allergies.

“Under Dr. Davis’ leadership, I have no doubt that our outstanding programs in Immunology, Allergy and Rheumatology will continue to flourish,” said Texas Children’s Physician-in-Chief Mark W. Kline. “Please join me in thanking Dr. Davis for her willingness to take on this important leadership role.”

May 9, 2017

Dr. Jordan Orange has been selected to receive a 2017 Michael E. DeBakey, M.D., Excellence in Research Award, a prestigious honor given annually to Baylor College of Medicine faculty who have made the most significant published scientific contribution to clinical or basic biomedical research during the past three years.

Orange’s peers – Drs. Emily Mace, Lisa Forbes and Tiphanie Vogel – nominated him for the award in honor of his work as a distinguished pediatrician-scientist who has made seminal contributions to the fields of clinical immunology, basic immunology and cell biology.

Specifically, they highlighted three papers that represent the breadth, caliber and recent impact of Orange’s work as chief of the Section of Immunology, Allergy and Rheumatology and director of the Center for Human Immunobiology. These papers were published in Nature Genetics, the Journal of Clinical Investigation and the Journal of Cell Biology and are described in greater detail below.

“Dr. Orange orchestrates a vibrant and successful clinical and basic research program applying cutting-edge cell biology to questions of important clinical relevance,” Mace said. “In addition to being a pioneer in the field of NK cell deficiency and an international authority in the study and treatment of primary immunodeficiency, he is also a world’s expert in the field of highly quantitative imaging, including super-resolution and total internal reflection microscopy.”

Mace added that Orange’s scientific accomplishments are paralleled only by his success as a leader and mentor.

“His scientific vision and innovation are combined with tireless dedication to both teaching and learning,” she said. “We all are honored to count him as a colleague.”

Orange will be presented with the DeBakey, M.D., Excellence in Research Award on May 15. To learn more about the award, click here. To learn more about the scientific research that garnered Orange the DeBakey award, see below.

Nature Genetics – Through collaboration with the Baylor Hopkins Center for Mendelian Genomics, Orange has become a leader in the discovery of novel monogenic causes of primary immunodeficiency. The discovery of COPA syndrome (Watkin et al., Nature Genetics 2015) was the result of a multi-institute collaboration led by Orange. This rare, autosomal dominant autoimmune syndrome leads to arthritis and interstitial lung disease and was identified through whole exome sequencing of affected patients and their unaffected family members. This genetic discovery was validated in Orange’s laboratory by identifying the mechanism of disease through modeling of the impacted pathway. This work was also recognized with the Lee C. Howley Sr. prize for the most outstanding paper of the year by the Arthritis Foundation in 2015.

Journal of Clinical Investigation – NK cells are innate lymphocytes that eliminate infected or diseased cells. The field of primary NK cell deficiency (NKD) is one in which Orange has been a pioneer; he penned one of the first descriptions of NKD in 2003. While rare, NKD is severe and frequently fatal. To date, four monogenic causes of isolated NKD have been published, two of these from Orange’s group. Most recently, Orange led an international team that discovered biallelic mutations in the transcription factor IRF8 are a novel cause of NKD. This paper, published in the Journal of Clinical Investigation in 2017 (Mace et al.), ended a decade-long quest to solve the original published case of NKD. Again, modeling of patient mutations in the Orange laboratory using cutting-edge cell biology revealed the mechanism of impaired NK cell development in a cohort of patients from unrelated families.

Cell Biology – As NK cells lie at the heart of Orange’s research, it is not surprising that understanding NK cell function has been a cornerstone of his basic science program. He has led the field of NK cell biology by using highly quantitative microscopy and image analysis to deeply probe their function. In the January 2017 issue of the Journal of Cell Biology, Hsu et al. describe the purpose of NK cell lytic granule convergence, a mechanism by which NK cells direct their potent cytolytic machinery to prevent damage to bystander cells. This finding, which has important clinical implications for the field of immunotherapy, featured the application of novel technology to mimic an NK cell microenvironment. This work was showcased on the cover of the journal and merited an editorial from the well-known cell biologist Dr. Ira Mellman, as well as a feature on the journal’s weekly podcast.

December 6, 2016

12716pediatricpilotawardinside900Dr. Jordan Orange, vice chair of research in the Department of Pediatrics, announced the winners of the 2016 Pediatric Pilot Awards Research Grant Program. Ten research applications were chosen by review committee members to receive grant funding in the amount of up to $50,000 for their projects.

The Pediatric Pilot Awards Research Grant Program provides initial start-up “seed funding” to support research projects. This grant program provides opportunities for new or less established researchers as well as experienced researchers who desire to expand their area of research. The grant projects are awarded based upon their scientific merit and the potential to generate the initial data necessary for a successful grant application submission to the National Institutes of Health or other external, peer-reviewed funding mechanisms.

The pilot award program is a collaborative effort between Texas Children’s Hospital and its academic partner, Baylor College of Medicine.

Congratulations to the following 2016 pilot grant awardees. View the names below to learn more about the research project being funded.

12716drsaurabhagarwal175Saurabh Agarwal, Ph.D.
Pediatrics – Hematology/Oncology
Epigenetic targeting of neuroblastoma cancer stem cells

More than half of the patients with high-risk neuroblastoma (NB) will relapse despite intensive multimodal therapy. Treatments for these patients are challenging due to disease heterogeneity, drug resistance, and toxicity. Thus, novel effective therapies are urgently required to specifically target those tumor cells which escape initial treatment and regenerate chemotherapy resistant recurrent disease.

We identified a G-CSF receptor expressing (CD114+) neuroblastoma cancer stem cell (CSC) subpopulation that is drug resistant, drives metastasis and may cause drug resistant relapse. These highly tumorigenic CSCs are distinguished by specific epigenetic alterations that lead to the expression of specific stem cell genes and maintenance of neuroblastoma CSCs.

We found that epigenetic modifiers MLL1 and JMJD3 increase the expression of G-CSF receptor gene (CSF3R) in NB CSCs by maintaining active histone modifications. Our pre-clinical studies show that blocking these epigenetic modifiers with specific small molecule inhibitors leads to neuroblastoma tumor regression and blockage of metastasis in vivo.

This pilot award will further enable us to test novel dual therapeutic approach by combining epigenetic inhibitors with standard chemotherapy for targeting both stem and non-stem neuroblastoma subpopulations. These studies will define specific epigenetic mechanisms contributing to the maintenance and tumorigenicity of NB CSCs, and pave the way for further clinical translation of our findings to block NB CSC-driven relapse and to advance a novel curative approach to neuroblastoma.
12716drwendyallenrhoades175Wendy Allen-Rhoades, M.D.
Pediatrics – Hematology/Oncology
Validation of a plasma microRNA panel as a biomarker for osteosarcoma

Osteosarcoma is the primary bone cancer in children and young adults. Currently, there are no reliable, non-invasive biological markers to detect the presence or progression of disease, assess therapy response or provide upfront prognostic insights. MicroRNAs (miRNAs) are evolutionarily conserved, stable, small non-coding RNA molecules that are key post-transcriptional regulators and are ideal candidates for circulating biomarker development due to their stability in plasma, ease of isolation and the unique expressions associated with specific disease states.

In our previous work, we analyzed more than 750 plasma miRNAs from a genetically engineered mouse model of osteosarcoma and identified a diagnostic panel of four plasma miRNAs. This diagnostic panel was able discriminate healthy from diseased animals. Subsequent analysis of 70 human patient samples corroborated these results and the diagnostic panel could discriminate healthy patients from patients with osteosarcoma. Furthermore, low plasma levels of miRNA-214 in metastatic patients at time of diagnosis were prognostic and conveyed a significantly better overall survival.

With the funding from the Pediatric Pilot Award, we will continue the necessary steps to fully validate this novel biomarker by completing validation of the diagnostic and prognostic miRNA biomarkers in 200 additional human samples. The long-term goal of this project is to test these new biomarkers in a prospective clinical trial.
12716drsaraanvari175Sara Anvari, M.D.
Pediatrics – Immunology, Allergy and Rheumatology
Defining biomarkers of successful peanut oral immunotherapy

Peanut allergy is one of the most common causes of severe and fatal allergic reactions related to food. The prevalence of peanut allergy has nearly tripled in the last 20 years and current standard of care for peanut allergy is strict avoidance of peanuts and ready access to emergency medications. While recent research has demonstrated that early introduction of peanuts, instead of avoidance, during infancy can greatly reduce the risk of a peanut allergy, this strategy is not applicable to individuals who have already developed an allergy.

For older children, teens, and adults, peanut oral immunotherapy (pOIT) is one method by which peanut allergies can be treated through step-wise introduction of peanut protein. This introduction is an effort to manage and reduce the allergic reactions in patients. However, how pOIT alters patients’ immune systems to recognize peanut protein as benign instead of “dangerous” (the nature of severe allergy) is poorly understood. Additionally, biomarkers, or testable indicators of efficacy, for pOIT success in a given patient are also still unknown at this time.

Most current research is focused on how pOIT modifies a white blood cell population, called T regulatory cells, which help control the severity of inflammation caused by immune reactions inside the human body. But T regulatory cells are just one end point of a larger set of immune reactions to pOIT. My research program will focus upstream of T regulatory cells on another population of white blood cells, called dendritic cells, which can communicate with and modify T regulatory cell, as well as several other types of white blood cells.

Specifically, the research award will help (1) identify biomarkers to predict a patient’s success (i.e. peanut tolerance) or failure (i.e. persistent peanut allergy) early in the course of pOIT, without waiting to complete three years of therapy; (2) development of targeted therapies for peanut allergic individuals aimed at altering dendritic cell populations to better modulate T regulatory populations which aid in the reduction of severe inflammatory reactions which make peanut allergies so life threatening.
12716drevelinebarbieri175Eveline Barbieri, M.D.
Pediatrics – Hematology/Oncology
Targeting MYCN-amplified neuroblastoma through RORa activation

The MYCN oncogene is a transcription factor frequently upregulated in high-risk neuroblastoma, which is profoundly involved in neuroblastoma initiation and progression. Thus, strategies antagonizing MYCN activity are a vital need in neuroblastoma therapy and the focus of this proposal.

Our laboratory has discovered that MYCN-driven neuroblastoma has an increased dependence on glutamine and lipid metabolism. Recent findings in other tumor types suggest an important link between these metabolic pathways and the circadian clock, which is disrupted in aggressive malignancies.

This led us to investigate how MYCN oncogenic signaling, circadian clock, and neuroblastoma metabolic tumor reprogramming are interrelated. Intriguingly, we have found that RORα signaling, a central component of circadian clock, is lost in MYCN-amplified neuroblastoma and this contributes to aberrant tumor proliferation.

Our specific aims will: 1) determine the metabolic programs activated by RORα in MYCN-driven tumors, and 2) determine the in vivo anti-tumor effects of RORα reactivation in pre-clinical neuroblastoma models. These studies will offer insights into critical molecular and metabolic alterations, which will provide new and more sensitive targets that could be strategically deployed with currently available therapies to treat this highly aggressive disease. Moreover, many enzymes in this pathway are amenable to small molecule inhibitors and therapeutic targeting of RORα-mediated metabolism is moving to the clinic.
12716drjennydespotovic175Jenny Despotovic, D.O.
Pediatrics – Hematology/Oncology
Genetic variants and gene expression patterns in acute and chronic immune thrombocytopenia

Immune thrombocytopenia (ITP) is an autoimmune disorder and one of the most common causes of low platelets in children. Twenty-five percent of affected children develop chronic ITP and some have significant morbidity and mortality. Currently, it is impossible to predict an individual patient’s clinical course and likelihood of spontaneous remission at the time of diagnosis.

Identification of children more likely to develop chronic ITP at diagnosis would improve treatment decisions and could also help identify important mechanisms of disease that could lead to more tailored treatment. Based on strong preliminary data produced in our laboratory, we believe that acute and chronic ITP are distinct diseases that can be distinguished at diagnosis; and specific genetic changes and gene expression differences influence the development of chronic ITP.

In our study, we are collecting DNA at enrollment on all patients with ITP, as well as RNA on patients with acute ITP at the time of diagnosis and at the time of disease resolution. For patients with chronic ITP, we are obtaining RNA at several time points. We will use the most current sequencing technologies to look for changes that may help explain differences between these two disorders with the eventual goal of identifying markers that could be used to distinguish the two disorders at diagnosis so that we could determine how to best approach each patient.
12716drjohnhollier175John Hollier, M.D.
Pediatrics – Gastroenterology
Efficacy of pre-recorded guided imagery session on pediatric gastrointestinal pain disorders managed in primary care

Up to 20 percent of school-age children and adolescents throughout the world are afflicted by recurring abdominal pain that cannot be explained by routine medical laboratory tests or procedures. These children miss more school and rank their general well-being much lower than their healthy counterparts. These disorders also may be associated with psychological distress like anxiety and depression.

One of the most effective treatments for these “functional gastrointestinal pain disorders” (FGIDs) fall under the category of cognitive behavioral therapy. However, access to this type of therapy often is not available due to lack of insurance coverage and/or scarcity of trained healthcare professionals.

Researchers have previously demonstrated the success of guided imagery, a type of cognitive behavioral therapy in treating FGIDs. Guided imagery can be delivered via using compact disc players so that patients can receive therapy at home. Our goal is to find out if audio-recorded guided imagery can be used to treat FGIDs when children are seen in the primary care setting (i.e., by their pediatrician or nurse practitioner). If so, we would be able to get treatment to these children sooner and likely decrease the need for them to be referred to a specialist (gastroenterologist). Our long term research goal is to use mobile cost effective technologies to improve the clinical care of patients with FGIDs and other pediatric diseases.
12716drandrewlandstrom175Andrew Landstrom, M.D.
Pediatrics – Cardiology
The role of junctophilin-2 in the regulation of cardiac nodal tissue

Diseases that impact the nodal tissue of the heart, such as the heart’s pacemaker, can be life-threatening. Children can suffer from these arrhythmias following surgery, through inheritance within families or for no identifiable reason. These arrhythmias can cause fainting, inability to play with the same energy as other children, or even death from collapse of the circulatory system. Despite how serious nodal disease can be, little is known about how these cells beat and how misbeats can occur. Since basic science has limited understanding of this specialized tissue, the therapies levied against nodal disease are toxic and can be ineffective.

A major reason for the lack of specialized therapies is the absence of experimental models which accurately reflect the arrhythmia. We have created an unparalleled mouse model with cardiac nodal disease that can be molecularly triggered to have arrhythmias from the nodal tissue of the heart. This mouse hosts a molecular switch which allows exposure to a pharmacological trigger to decrease the amount of a protein named junctophilin-2 (Jph2) specifically in the heart.

We have previously shown that reduction in the normal amount of Jph2 in the muscle cells of the heart causes calcium to leak into the cell. This causes a loss of contractile force and cardiac failure. We have also found that human mutations in the gene which encodes Jph2 can lead to cardiac hypertrophy as well as atrial fibrillation. All of these diseases are associated with early, and sometimes sudden, death. We have recently found that expression silencing of Jph2 specifically in the nodal tissue results in a rapid resting heart rate and an arrhythmia known as accelerated junctional rhythm. Our early studies have given strong evidence that this mouse has nodal disease that is very similar to many of the children which suffer from nodal dysrhythmias.

With support from pilot research grant, we hope to delve into the physiology of the cardiac pacemaker and to discover the molecular causes of nodal arrhythmias. We believe that the same calcium signaling that becomes perturbed in the muscle cells of the heart may be to blame for these arrhythmias. Careful interrogation of this possibility, and dissection of the molecular underpinnings of this mouse’s arrhythmias, will offer the first insights into the nodal diseases which remain unexplained and ineffectively treated.
12716drjennettemoreno175Jennette Moreno, Ph.D.
Pediatrics – Nutrition
Assessment of differences in children’s circadian rhythms during the school year and summer vacation

Consistent evidence indicates that school age children demonstrate improvements in their weight status during the school year, yet gain substantial weight during summer. These summertime increases in body mass index (BMI) increase children’s risk for becoming overweight or obese. Further, children at risk for developing chronic health conditions associated with obesity are more likely to demonstrate increases in BMI during summer. Preventing increases in children’s weight during summer may be an important opportunity to address the obesity epidemic in children.

Obesity is conventionally considered a problem of imbalance in energy intake (diet) and expenditure (physical activity/sedentary behavior). There is growing awareness of the role of sleep and circadian rhythms in the development of obesity, yet differences in children’s sleep and circadian rhythms during the school year and summer have not been examined.

Circadian rhythms are internal processes present in all living things that operate on a roughly 24 hour cycle. Behavioral rhythms such as the timing of meals and going to bed and waking up at a consistent time are some of the behaviors known to promote stable circadian rhythms. Changes in sleep and behavioral rhythms may result in disruption of circadian rhythms. Because summer vacation is associated with changes in children’s sleep and behavioral rhythms, the school year and summer vacation paradigm offer an important opportunity to expand our scientific understanding of the role of disruptions in sleep and circadian rhythms on the development of obesity in children.

Little is known about differences in children’s sleep and circadian rhythms during the school year and summer. With the current proposal, we plan to address this gap in scientific knowledge by measuring differences in children’s sleep and circadian rhythms during the school year and summer. We will assess whether differences in sleep and circadian rhythms are related to changes in children’s weight during the school year and summer. These data will may lead to novel approaches to the prevention of obesity in children.
12716drrobinparihar175Robin Parihar, M.D.
Pediatrics –Hematology/Oncology
Testing a novel non-invasive method to assess efficacy of tumor microenvironment-directed immune therapy

Some children with cancer have solid tumors, or collections of abnormally growing cells, within their organs. These collections are made up of mostly cancer cells, but also of accessory cells that help the tumor hide from the body’s immune system and grow – collectively called the tumor microenvironment. Our laboratory created a new type of immune therapy to specifically target and destroy these accessory cells found within the tumor microenvironment so that they can’t help the cancer grow.

One of the main problems for testing our immune therapy in patients with solid tumors is that we can’t detect these accessory cells without performing a biopsy procedure of the tumor inside the body. In order to detect the accessory cells in patients at many different times during their therapy, we would have to perform repeated invasive biopsy procedures, which come with additional risks and costs. There is currently no non-invasive method by which to determine the effectiveness of therapies that target the tumor microenvironment. If strategies targeting the tumor microenvironment are to be tested in humans, non-invasive methods will need to be developed to evaluate their effectiveness, thereby circumventing the need for repeated invasive biopsies.

Our project involves the creation and testing of a new type of CAT scan that can indirectly detect the accessory cells of the tumor microenvironment. If successful, our new CAT scan can be used to detect changes in the number of accessory cells in patients receiving our new immune therapy, without the need for repeated invasive, risky, or costly procedures. This new CAT scan can be used in clinical trials of other immune therapies as well and may be applied to both children and adults with cancer. The long term goal of the project is to develop a clinical imaging tool that will allow doctors to follow changes within the tumor microenvironment induced by immune therapies.
12716drsarahsartain175Sarah Sartain, M.D.
Pediatrics – Hematology/Oncology
The linkage between hemostasis-thrombosis, complement, and inflammation in the pathophysiology of thrombotic microangiopathy

The goal of our research is to improve the health of patients with thrombotic microangiopathy, a group of disorders that cause anemia, low platelets, clots in the blood vessels, and blood vessel damage of the brain, heart, and kidneys. The mechanisms of small blood vessel damage in thrombotic microangiopathy are not precisely defined.

We will investigate the means by which thrombotic microangiopathy causes blood vessel injury and organ damage. We believe that the immune system is involved in the process of vessel injury in thrombotic microangiopathy. This is based on previous work showing that components of the immune system known as the “alternative complement pathway” bind to, and become activated on, long and sticky von Willebrand factor (VWF) strings secreted from blood vessel walls. These VWF strings normally attract platelets to initiate blood clot formation. We intend to determine if activated alternative complement components on these strings contribute to blood vessel injury. We will also determine if a powerful molecule produced during inflammation (known as “tumor necrosis factor”) controls activation of the alternative complement pathway on the VWF strings, contributing to heart, brain, and kidney blood vessel injury.

Our proposed research has long-term biomedical significance because determining the mechanisms of blood vessel/organ injury in thrombotic microangiopathy will lead to the development of therapies to improve the outcomes in this disorder and may be applicable to more common types of blood vessel injury in the general population.

June 10, 2014

61114DavidClinic640

FFirst, it was the construction of Texas Children’s new pediatric community hospital in The Woodlands slated to open in 2017. Now, a new David Clinic will be built at The Woodlands campus, which means children affected by immune deficiencies will receive world class care and diagnosis in their own community.

On June 4, David Elementary School presented Texas Children’s with a donation of more than $38,000 raised by students and families that will be used to construct the new facility.

The facility will serve as an extension of the already established David Center at Texas Children’s main campus, which provides care and research for primary immune deficiencies, which are inborn diseases of the immune system that make children susceptible to auto immunity and infectious diseases.

“With the growing city of Houston and Texas Children’s Hospital facilities, it makes sense to put an extension of the David Center in David’s own community and in our new hospital in The Woodlands to increase awareness and provide greater access to patient care and treatment,” said Dr. Jordan Orange, chief of Immunology, Allergy and Rheumatology at Texas Children’s.

The David Clinic and the David Center are named in honor of David Vetter, the Texas Children’s Hospital patient from the 1970s known as the “Bubble Boy,” who suffered from Severe Combined Immune Deficiency (SCID), which required him to live in a plastic bubble to protect him from germs and bacteria.

“This rare illness that David succumbed to affects about 1 in 50,000 babies,” said Dr. Orange. “Due to remarkable advances in immunology research and treatment, this immune deficiency is almost 100 percent curable if identified within the first three months of life.”

Since December 2012, every baby born in Texas is screened for SCID to ensure prompt diagnosis and best outcomes.

Besides the generous gift from David Elementary School, which is also named after Vetter, the school hosted David’s Dream Run last month. This annual event has raised more than $350,000 since its inception and all proceeds support The David Center and its research. All funds from the run through 2016 will support construction of the David Clinic in The Woodlands.

To learn more about David, visit the artifacts exhibit on the third floor of the Feigin Center in the Allergy and Immunology department. The David Center Wall on the ninth floor of the Clinical Care Center features a collection of photos highlighting David’s long-term association with Texas Children’s.